FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy
Status:
Recruiting
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies F-18 16 alpha-fluoroestradiol (FES) positron emission tomography
(PET)/computed tomography (CT) in predicting response to endocrine therapy in patients with
newly diagnosed breast cancer that has spread to other parts of the body. FES is a
radioactive form of the hormone estrogen and may "light up" where cancer is in the body.
Diagnostic procedures using FES, such as FES PET/CT, may help measure the FES and help
doctors predict how well the cancer will respond to treatment.